Skip to main content
PMC home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1995 Feb;48(2):147–150. doi: 10.1136/jcp.48.2.147

Immunohistochemical study of topoisomerase II-alpha expression in primary ductal carcinoma of the breast.

P Hellemans 1, P A van Dam 1, M Geyskens 1, A T van Oosterom 1, P Buytaert 1, E Van Marck 1
PMCID: PMC502388  PMID: 7745115

Abstract

AIMS--To study the patterns of expression of topoisomerase II-alpha in primary invasive ductal breast carcinomas; to correlate this expression with clinicopathological data and prognosis. METHODS--Cryostat sections from 63 primary invasive ductal breast carcinomas were stained immunohistochemically for topoisomerase II-alpha. Nuclear immunoreactivity was quantified by counting at least 500 cells in different random fields and results were expressed as per cent of cells staining positively for topoisomerase II-alpha. RESULTS--Topoisomerase II-alpha nuclear immunoreactivity (median 14% of nuclei; range 2-62%) was detected in all tumours with highly variable intertumour and intratumour nuclear reactivity. Higher levels of topoisomerase II-alpha expression were strongly related to higher tumour grade, larger tumour size, nodal status, and the presence of distant metastases at diagnosis. No correlation was found with menopausal status, steroid hormone receptor status, disease free survival, or overall survival. CONCLUSIONS--Expression of topoisomerase II-alpha is related to the presence of poor prognostic factors. Immunohistochemical assessment of topoisomerase II-alpha expression in breast cancer could be potentially useful for tailoring chemotherapy with topoisomerase II inhibitors.

Full text

PDF
147

Images in this article

149Image
on p.149

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BLOOM H. J., RICHARDSON W. W. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957 Sep;11(3):359–377. doi: 10.1038/bjc.1957.43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Chung T. D., Drake F. H., Tan K. B., Per S. R., Crooke S. T., Mirabelli C. K. Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes. Proc Natl Acad Sci U S A. 1989 Dec;86(23):9431–9435. doi: 10.1073/pnas.86.23.9431. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cummings J., Smyth J. F. DNA topoisomerase I and II as targets for rational design of new anticancer drugs. Ann Oncol. 1993 Aug;4(7):533–543. doi: 10.1093/oxfordjournals.annonc.a058584. [DOI] [PubMed] [Google Scholar]
  4. Davies S. M., Robson C. N., Davies S. L., Hickson I. D. Nuclear topoisomerase II levels correlate with the sensitivity of mammalian cells to intercalating agents and epipodophyllotoxins. J Biol Chem. 1988 Nov 25;263(33):17724–17729. [PubMed] [Google Scholar]
  5. De Negri F., Campani D., Sarnelli R., Martini L., Gigliotti A., Bonacci R., Fabbri R., Squartini F., Pinchera A., Giani C. Comparison of monoclonal immunocytochemical and immunoenzymatic methods for steroid receptor evaluation in breast cancer. Am J Clin Pathol. 1991 Jul;96(1):53–58. doi: 10.1093/ajcp/96.1.53. [DOI] [PubMed] [Google Scholar]
  6. Drake F. H., Hofmann G. A., Bartus H. F., Mattern M. R., Crooke S. T., Mirabelli C. K. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry. 1989 Oct 3;28(20):8154–8160. doi: 10.1021/bi00446a029. [DOI] [PubMed] [Google Scholar]
  7. Epstein R. J., Smith P. J. Estrogen-induced potentiation of DNA damage and cytotoxicity in human breast cancer cells treated with topoisomerase II-interactive antitumor drugs. Cancer Res. 1988 Jan 15;48(2):297–303. [PubMed] [Google Scholar]
  8. Epstein R. J., Smith P. J., Watson J. V., Waters C., Bleehen N. M. Oestrogen potentiates topoisomerase-II-mediated cytotoxicity in an activated subpopulation of human breast cancer cells: implications for cytotoxic drug resistance in solid tumours. Int J Cancer. 1989 Sep 15;44(3):501–505. doi: 10.1002/ijc.2910440321. [DOI] [PubMed] [Google Scholar]
  9. Friedman M. A. New directions for breast cancer therapeutic research. Hematol Oncol Clin North Am. 1994 Feb;8(1):113–119. [PubMed] [Google Scholar]
  10. Fry A. M., Chresta C. M., Davies S. M., Walker M. C., Harris A. L., Hartley J. A., Masters J. R., Hickson I. D. Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines. Cancer Res. 1991 Dec 15;51(24):6592–6595. [PubMed] [Google Scholar]
  11. Holden J. A., Rolfson D. H., Wittwer C. T. Human DNA topoisomerase II: evaluation of enzyme activity in normal and neoplastic tissues. Biochemistry. 1990 Feb 27;29(8):2127–2134. doi: 10.1021/bi00460a024. [DOI] [PubMed] [Google Scholar]
  12. Keith W. N., Douglas F., Wishart G. C., McCallum H. M., George W. D., Kaye S. B., Brown R. Co-amplification of erbB2, topoisomerase II alpha and retinoic acid receptor alpha genes in breast cancer and allelic loss at topoisomerase I on chromosome 20. Eur J Cancer. 1993;29A(10):1469–1475. doi: 10.1016/0959-8049(93)90022-8. [DOI] [PubMed] [Google Scholar]
  13. Markovits J., Pommier Y., Kerrigan D., Covey J. M., Tilchen E. J., Kohn K. W. Topoisomerase II-mediated DNA breaks and cytotoxicity in relation to cell proliferation and the cell cycle in NIH 3T3 fibroblasts and L1210 leukemia cells. Cancer Res. 1987 Apr 15;47(8):2050–2055. [PubMed] [Google Scholar]
  14. Negri C., Chiesa R., Cerino A., Bestagno M., Sala C., Zini N., Maraldi N. M., Astaldi Ricotti G. C. Monoclonal antibodies to human DNA topoisomerase I and the two isoforms of DNA topoisomerase II: 170- and 180-kDa isozymes. Exp Cell Res. 1992 Jun;200(2):452–459. doi: 10.1016/0014-4827(92)90195-e. [DOI] [PubMed] [Google Scholar]
  15. Potmesil M., Hsiang Y. H., Liu L. F., Bank B., Grossberg H., Kirschenbaum S., Forlenza T. J., Penziner A., Kanganis D., Forlenzar T. J. Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II. Cancer Res. 1988 Jun 15;48(12):3537–3543. [PubMed] [Google Scholar]
  16. Shapiro C. L., Henderson I. C. Adjuvant therapy of breast cancer. Hematol Oncol Clin North Am. 1994 Feb;8(1):213–231. [PubMed] [Google Scholar]
  17. Smith K., Houlbrook S., Greenall M., Carmichael J., Harris A. L. Topoisomerase II alpha co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity. Oncogene. 1993 Apr;8(4):933–938. [PubMed] [Google Scholar]
  18. Smith P. J., Makinson T. A. Cellular consequences of overproduction of DNA topoisomerase II in an ataxia-telangiectasia cell line. Cancer Res. 1989 Mar 1;49(5):1118–1124. [PubMed] [Google Scholar]
  19. Tan K. B., Dorman T. E., Falls K. M., Chung T. D., Mirabelli C. K., Crooke S. T., Mao J. Topoisomerase II alpha and topoisomerase II beta genes: characterization and mapping to human chromosomes 17 and 3, respectively. Cancer Res. 1992 Jan 1;52(1):231–234. [PubMed] [Google Scholar]
  20. Tsai-Pflugfelder M., Liu L. F., Liu A. A., Tewey K. M., Whang-Peng J., Knutsen T., Huebner K., Croce C. M., Wang J. C. Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22. Proc Natl Acad Sci U S A. 1988 Oct;85(19):7177–7181. doi: 10.1073/pnas.85.19.7177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Volm M., Mattern J., Efferth T., Pommerenke E. W. Expression of several resistance mechanisms in untreated human kidney and lung carcinomas. Anticancer Res. 1992 Jul-Aug;12(4):1063–1067. [PubMed] [Google Scholar]
  22. Woessner R. D., Mattern M. R., Mirabelli C. K., Johnson R. K., Drake F. H. Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ. 1991 Apr;2(4):209–214. [PubMed] [Google Scholar]
  23. Zini N., Martelli A. M., Sabatelli P., Santi S., Negri C., Astaldi Ricotti G. C., Maraldi N. M. The 180-kDa isoform of topoisomerase II is localized in the nucleolus and belongs to the structural elements of the nucleolar remnant. Exp Cell Res. 1992 Jun;200(2):460–466. doi: 10.1016/0014-4827(92)90196-f. [DOI] [PubMed] [Google Scholar]
  24. van der Zee A. G., Hollema H., de Jong S., Boonstra H., Gouw A., Willemse P. H., Zijlstra J. G., de Vries E. G. P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res. 1991 Nov 1;51(21):5915–5920. [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES